Answers are grounded in this paper and cite their sources.
Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Manco‐Johnson et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: